Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 8, 2009, Pages 1276-1283

  Lazo Langner, A ^a   Monkman, K ^a   Kovacs, Michael J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

CYP2C9; Dose prediction; Nomogram; Venous thromboembolism; VKORC1; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ACCURACY; ADULT; ARTICLE; BOOTSTRAPPING; DOSE RESPONSE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; NONPARAMETRIC TEST; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; VENOUS THROMBOEMBOLISM;

COHORT STUDIES; DRUG DOSAGE CALCULATIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MODELS, THEORETICAL; NOMOGRAMS; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 67949086757     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03483.x     Document Type: Article

References (38)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S.
2. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-6.
3. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest 2005; 127: 2049-56.
4. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62.
5. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
6. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
7. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
8. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
9. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
10. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007; 5: 8-16.
11. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
12. Lenzini PA, Grice GR, Milligan PE, Gatchel SK, Deych E, Eby CS, Burnett RS, Clohisy JC, Barrack RL, Gage BF. Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother 2007; 41: 1798-804.
13. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
14. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110: 1511-5.
15. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
16. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW. Estimation of warfarin maintenance dose based on VKORC1 (-1639G>A) and CYP2C9 genotypes. Clin Chem 2007; 53: 1199-205.
17. Warfarin (Coumadin ®) prescribing information. Food and Drug Administration, August 2007; http://www.fda.gov/cder/foi/label/2007/ 009218s105lblv2.pdf. Accessed 25 February 2009.
18. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-92.
19. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E, Wells PS. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003; 138: 714-9.
20. Monkman K, Lazo-Langner A, Kovacs MJ. A 10mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. Thromb Res 2009; DOI: 10.1016/j.thromres.2008.12.001
21. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
22. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
23. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE, Morrow B, Clement AM, Wells PS. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 1650-3.
24. Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 1984; 288: 1268-70.
25. Shine D, Patel J, Kumar J, Malik A, Jaeger J, Maida M, Ord L, Burrows G. A randomized trial of initial warfarin dosing based on simple clinical criteria. Thromb Haemost 2003; 89: 297-304.
26. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
27. Henderson AR. The bootstrap: A technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta 2005; 359: 1-26.
28. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
29. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009; 113: 3925-30.
30. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-70.
31. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 2007; 83: 460-70.
32. Routledge PA, Davies DM, Bell SM, Cavanagh JS, Rawlins MD. Predicting patients' warfarin requirements. Lancet 1977; 2: 854-5.
33. Sawyer WT, Poe TE, Canaday BR, Weiner JS, Williams DM, Webb CE, Ellison MJ. Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response. Clin Pharm 1985; 4: 440-6.
34. Sharma NK, Routledge PA, Rawlins MD, Davies DM. Predicting the dose of warfarin for therapeutic anticoagulation. Thromb Haemost 1982; 47: 230-1.
35. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahe I, Donval V, Seux ML, Romain-Pilotaz M, Gisselbrecht M, Verny M, Pautas E. Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am J Med 2005; 118: 137-42.
36. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4.
37. Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, Hillman MA. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. Clin Med Res 2005; 3: 207-13.
38. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150: 73-83.